Expanded Human Immunodeficiency Virus (HIV) Testing for Disproportionately Affected Populations, 51273-51275 [2010-20572]

Download as PDF 51273 Federal Register / Vol. 75, No. 160 / Thursday, August 19, 2010 / Notices A.12–1—ESTIMATES OF NET HOUR BURDEN REDUCTION Type of respondents Number of respondents Stage 1: Immediate ......................................................................... Stage 1: Expected Reduction in Current burden (assuming 100 universities and at median) .......................................................... Net reduction in burden ................................................................... Stage 1: Future ................................................................................ Stage 2: Expected Reduction in Current burden (assuming 100 universities and at median) .......................................................... Net reduction in burden ................................................................... Request for Comments: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. FOR FURTHER INFORMATION CONTACT: To emcdonald on DSK2BSOYB1PROD with NOTICES request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Dr. Stefano Bertuzzi, Health Science Policy Analyst, Office of Science and Technology Policy, OSP, OD; NIH, Building 1, Room 218, 9000 Rockville Pike, Bethesda, MD 20892 or call non-toll-free number 301– 495–9286 or e-mail your request, including your address to: stefano.bertuzzi@nih.gov. Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication. Dated: August 12, 2010. Lynn D. Hudson, Director, Office of Science Policy Analysis, National Institutes of Health. 1 72 +7,200 100 100 100 4 4 4 40 ............................ 1.0 ¥16,000 ¥8,800 +400 100 100 4 4 40 ............................ ¥16,000 ¥15,600 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [60 Day-10–0798] Proposed Data Collections Submitted for Public Comment and Recommendations; Correction Centers for Disease Control and Prevention Notice; Correction The Centers for Disease Control and Prevention published a document in the Federal Register titled 60-day 10–0798. The document contained the incorrect OMB number and expiration date. FOR FURTHER INFORMATION CONTACT: Maryam Daneshvar, 404–639–4604 Correction In the Federal Register of August 12, 2010, Volume 75, Number 155, in FR Doc. 2010–19911 page 48972, under the Proposed Project paragraph correct (OMB No. 0920–0753 exp. 10/31/2010) to read: (OMB No. 0920–0798 exp. 1/31/ 2011). Dated: August 12, 2010. Maryam I, Daneshvar, Reports Clearance Officer, Centers for Disease Control and Prevention. [FR Doc. 2010–20570 Filed 8–18–10; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention (CDC) [FR Doc. 2010–20614 Filed 8–18–10; 8:45 am] BILLING CODE 4140–01–P AGENCY: 17:05 Aug 18, 2010 Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). Jkt 220001 PO 00000 Frm 00036 Fmt 4703 Annual hour burden 100 Expanded Human Immunodeficiency Virus (HIV) Testing for Disproportionately Affected Populations VerDate Mar<15>2010 Average time per response (in hours) Frequency of response Sfmt 4703 ACTION: Notice. Notice of Intent to increase funding available to make awards under the Centers for Disease Control and Prevention Funding Opportunity Announcement CDC–RFA–PS10–10138, ‘‘Expanded Human Immunodeficiency Virus (HIV) Testing for Disproportionately Affected Populations’’. Additional funding from the Patient Protection and Affordable Care Act has been allocated for awards to state and county and local public health departments with at least 175 estimated combined AIDS diagnoses among Blacks/African Americans and Hispanics/Latinos in 2007. SUMMARY: This notice provides public notice of CDC’s intent to increase available funding for the Centers for Disease Control and Prevention Funding Opportunity Announcement PS10– 10138, ‘‘Expanded Human Immunodeficiency Virus (HIV) Testing for Disproportionately Affected Populations’’ to make awards to state and county and local public health departments. It is the intent of CDC to increase the amount of funds available to applicants who applied for awards under the previously announced funding opportunity CDC–RFA–PS10– 10138, which closed on June 24, 2010. CDC received additional funding through the Patient Protection Affordable Care Act (PPACA), Section 4002 Prevention and Public Health Fund. Accordingly CDC adds the following information to the previously published funding opportunity announcement: —Catalog of Federal Domestic Assistance Number: 93.523 The Affordable Care Act: Human Immunodeficiency Virus (HIV) Prevention and Public Health Fund Activities. —Authority: This program is authorized under Sections 301 and 318 of the Public Health Service Act (42 U.S.C. Section 241 and 247c), as amended, and Section 4002 of the Patient E:\FR\FM\19AUN1.SGM 19AUN1 51274 Federal Register / Vol. 75, No. 160 / Thursday, August 19, 2010 / Notices Protection and Affordable Care Act (Pub. L. 111–148). —Reporting Requirements: Recipients of the PPACA funds through this funding opportunity announcement are required to comply with the reporting requirements, terms and conditions set forth in the published version of the PS10–10138, ‘‘Expanded Human Immunodeficiency Virus (HIV) Testing for Disproportionately Affected Populations’’ (CDC–RFA–PS10– 10138). —CFDA Number 93.523 The Affordable Care Act: Human Immunodeficiency Virus (HIV) Prevention and Public Health Fund Activities is the PPACAspecific CFDA number for this initiative. It is included in addition to the CFDA Number 93.940, HIV Prevention Activities for Health Departments, published in the abovereferenced Funding Opportunity Announcement (FOA). Award Information: Type of Award: Cooperative Agreement. Fiscal Year Funds: Fiscal Year 2010, Funding for this announcement will include a combination of HIV Prevention funding and funds from the PPACA, Prevention and Public Health Fund. Available funding amounts, including the additional PPHF funds, are as follows. Part A—HIV Screening and HIV Counseling, Testing, and Referral Approximate Current Fiscal Year Funding: Up to $60,000,000 total (to include up to $55,633,000 in Enhanced HIV Testing funds and adding $4,367,000 in Patient Protection and Affordable Care Act of 2010 funds). Approximate Total Project Period Funding: $166,899,000. (This amount is an estimate, and is subject to availability of funds. This amount includes direct and indirect costs.) Approximate Number of Awards: 30. Approximate Average Award: $2,000,000. The average awards will be proportionately based on estimated combined 2007 Black/African American and Hispanic/Latino AIDS diagnoses for eligible jurisdictions. (These amounts are for the first 12-month budget period, and include both direct and indirect costs.) Floor and Ceiling of Individual Award Ranges: Floor of individual award range Jurisdiction Florida .............................................................................................................................................................. New York City .................................................................................................................................................. California .......................................................................................................................................................... Texas ............................................................................................................................................................... New York State ................................................................................................................................................ Georgia ............................................................................................................................................................ Maryland .......................................................................................................................................................... North Carolina .................................................................................................................................................. Louisiana .......................................................................................................................................................... Puerto Rico ...................................................................................................................................................... Houston ............................................................................................................................................................ District of Columbia ......................................................................................................................................... New Jersey ...................................................................................................................................................... Philadelphia ..................................................................................................................................................... South Carolina ................................................................................................................................................. Chicago ............................................................................................................................................................ Virginia ............................................................................................................................................................. Los Angeles ..................................................................................................................................................... Pennsylvania .................................................................................................................................................... Michigan ........................................................................................................................................................... Tennessee ....................................................................................................................................................... Illinois ............................................................................................................................................................... Ohio ................................................................................................................................................................. Massachusetts ................................................................................................................................................. Alabama ........................................................................................................................................................... Mississippi ........................................................................................................................................................ Connecticut ...................................................................................................................................................... Missouri ............................................................................................................................................................ Arizona ............................................................................................................................................................. San Francisco .................................................................................................................................................. $4,307,446 3,998,517 2,482,306 2,094,529 1,861,862 1,788,184 1,700,288 1,303,462 1,302,170 1,258,222 1,197,470 1,140,596 1,059,163 1,042,359 985,485 968,681 852,348 803,229 801,937 798,059 774,792 707,578 684,311 667,507 642,948 605,463 602,878 549,881 542,126 476,204 REVISED Ceiling of individual award range* $6,818,721 6,329,161 3,926,423 3,311,912 2,943,206 2,826,449 2,687,160 2,058,310 2,056,262 1,986,618 1,890,344 1,800,216 1,671,169 1,644,540 1,554,411 1,527,782 1,343,429 1,265,591 1,263,543 1,257,398 1,220,527 1,114,012 1,077,141 1,050,512 1,011,593 952,191 948,093 864,111 851,820 747,353 * These ceilings are for the first 12-month budget period and include direct and indirect costs. emcdonald on DSK2BSOYB1PROD with NOTICES Part B—Enhanced Linkage to Medical Care and Partner Services Approximate Current Fiscal Year Funding: $4,000,000. Approximate Total Project Period Funding: $12,000,000 (This amount is an estimate, and is subject to availability of funds. This amount includes direct and indirect costs.) Approximate Number of Awards: Up to 20. VerDate Mar<15>2010 17:05 Aug 18, 2010 Jkt 220001 Approximate Average Award: $200,000 (This amount is for the first 12-month budget period, and includes both direct and indirect costs.) Floor of Individual Award Range: $ 150,000. Ceiling of Individual Award Range: $ 225,000 (This ceiling is for the first 12month budget period and includes direct and indirect costs.) PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 Both Part A (HIV Screening and HIV Counseling, Testing, and Referral) and Part B (Enhanced Linkage to Medical Care and Partner Services) Anticipated Award Date: September 30, 2010. Budget Period Length: 12 months. Project Period Length: 3 years (Availability of PPACA funds beyond the initial 12 months will be based on availability of future funding.) E:\FR\FM\19AUN1.SGM 19AUN1 Federal Register / Vol. 75, No. 160 / Thursday, August 19, 2010 / Notices Throughout the project period, CDC’s commitment to continuation of awards will be conditioned on the availability of funds, evidence of satisfactory progress by the recipient (as documented in required reports), and the determination that continued funding is in the best interest of the Federal government. Application Selection Process CDC will apply the same selection methodology published in the CDC– RFA–PS10–10138. Funding Authority CDC will add the PPACA Authority to that which is currently reflected in the published Funding Opportunity CDC– RFA–PS10–10138. The revised funding authority language will read: —This program is authorized under Sections 301 and 318 of the Public Health Service Act (42 U.S.C. Section 241 and 247c), as amended, and Section 4002 of the Patient Protection and Affordable Care Act (Pub. L. 111– 148). DATES: The effective date for this action is August 19, 2010 and remains in effect until the expiration of the project period of the PPACA funded applications. FOR FURTHER INFORMATION CONTACT: Elmira Benson, Acting Deputy Director, Centers for Disease Control and Prevention, 2920 Brandywine Road, Atlanta, GA 30341, telephone (770) 488–2802, e-mail: Elmira.Benson@cdc.gov. On March 23, 2010, the President signed into law the Patient Protection and Affordable Care Act (PPACA), Public Law 111–148. PPACA is designed to improve and expand the scope of health care coverage for Americans. Cost savings through disease prevention is an important element of this legislation and PPACA has established a Prevention and Public Health Fund (PPHF) for this purpose. Specifically, the legislation states in Section 4002 that the PPHF is to ‘‘provide for expanded and sustained national investment in prevention and public health programs to improve health and help restrain the rate of growth in private and public sector health care costs.’’ PPACA and the Prevention and Public Health Fund make improving public health a priority with investments to improve public health. The PPHF states that the Secretary shall transfer amounts in the Fund to accounts within the Department of Health and Human Services to increase funding, over the fiscal year 2008 level, for programs authorized by the Public emcdonald on DSK2BSOYB1PROD with NOTICES SUPPLEMENTARY INFORMATION: VerDate Mar<15>2010 17:05 Aug 18, 2010 Jkt 220001 Health Service Act, for prevention, wellness and public health activities including prevention research and health screenings, such as the Community Transformation Grant Program, the Education and Outreach Campaign for Preventative Benefits, and Immunization Programs. PPACA legislation affords an important opportunity to advance public health across the lifespan and to reduce health disparities by supporting an intensive community approach to chronic disease prevention and control. Therefore, increasing funding available to applicants under this FOA using the PPHF to further HIV prevention programs is consistent with the purpose of the PPHF, as stated above, to provide for an expanded and sustained national investment in prevention and public health programs. Further, the Secretary allocated funds to CDC, pursuant to the PPHF, for the types of activities this FOA is designed to carry out. Dated: August 13, 2010. Tanja Popovic, MD, PhD, F(AMM), AM(AAFS), Deputy Associate Director for Science, Centers for Disease Control and Prevention. 51275 applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Dental and Craniofacial Research Council. Date: September 27, 2010. Open: 8:30 a.m. to 12:30 p.m. Agenda: Report of the Director, NIDCR. Place: National Institutes of Health, Building 31C, 31 Center Drive, 6th Floor, 10, Bethesda, MD 20892. Closed: 1:30 p.m. to Adjournment. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Building 31C, 31 Center Drive, 6th Floor, 10, Bethesda, MD 20892. Contact Person: Alicia J. Dombroski, PhD, Director, Division of Extramural Activities, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892. Information is also available on the Institute’s/Center’s home page: http:// www.nidcr.nih.gov/about, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS) [FR Doc. 2010–20572 Filed 8–18–10; 8:45 am] Dated: August 13, 2010. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. BILLING CODE P [FR Doc. 2010–20610 Filed 8–18–10; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institute of Dental and Craniofacial Research; Notice of Meeting National Institutes of Health Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory Dental and Craniofacial Research Council. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Subcommittee for Planning the Annual Strategic Plan Updating Process of the Interagency Autism Coordinating Committee (IACC). The Subcommittee meeting will be conducted as a telephone conference call and webinar. PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 National Institute of Mental Health; Notice of Meeting Name of Committee: Interagency Autism Coordinating Committee (IACC). Type of Meeting: Subcommittee for Planning the Annual Strategic Plan Updating Process. Date: September 21, 2010. Time: 1 p.m. to 3 p.m. Eastern Time. Agenda: To discuss plans for updating the IACC Strategic Plan for ASD Research. Place: No in-person meeting; conference call and webinar only. Webinar Access: https://www2. gotomeeting.com/register/461944091. Registration: No pre-registration required. Conference Call: Dial: 800–369–3340. Access code: 8415008. E:\FR\FM\19AUN1.SGM 19AUN1

Agencies

[Federal Register Volume 75, Number 160 (Thursday, August 19, 2010)]
[Notices]
[Pages 51273-51275]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-20572]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention (CDC)


Expanded Human Immunodeficiency Virus (HIV) Testing for 
Disproportionately Affected Populations

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

    Notice of Intent to increase funding available to make awards under 
the Centers for Disease Control and Prevention Funding Opportunity 
Announcement CDC-RFA-PS10-10138, ``Expanded Human Immunodeficiency 
Virus (HIV) Testing for Disproportionately Affected Populations''. 
Additional funding from the Patient Protection and Affordable Care Act 
has been allocated for awards to state and county and local public 
health departments with at least 175 estimated combined AIDS diagnoses 
among Blacks/African Americans and Hispanics/Latinos in 2007.
SUMMARY: This notice provides public notice of CDC's intent to increase 
available funding for the Centers for Disease Control and Prevention 
Funding Opportunity Announcement PS10-10138, ``Expanded Human 
Immunodeficiency Virus (HIV) Testing for Disproportionately Affected 
Populations'' to make awards to state and county and local public 
health departments. It is the intent of CDC to increase the amount of 
funds available to applicants who applied for awards under the 
previously announced funding opportunity CDC-RFA-PS10-10138, which 
closed on June 24, 2010.
    CDC received additional funding through the Patient Protection 
Affordable Care Act (PPACA), Section 4002 Prevention and Public Health 
Fund. Accordingly CDC adds the following information to the previously 
published funding opportunity announcement:
--Catalog of Federal Domestic Assistance Number: 93.523 The Affordable 
Care Act: Human Immunodeficiency Virus (HIV) Prevention and Public 
Health Fund Activities.
--Authority: This program is authorized under Sections 301 and 318 of 
the Public Health Service Act (42 U.S.C. Section 241 and 247c), as 
amended, and Section 4002 of the Patient

[[Page 51274]]

Protection and Affordable Care Act (Pub. L. 111-148).
--Reporting Requirements: Recipients of the PPACA funds through this 
funding opportunity announcement are required to comply with the 
reporting requirements, terms and conditions set forth in the published 
version of the PS10-10138, ``Expanded Human Immunodeficiency Virus 
(HIV) Testing for Disproportionately Affected Populations'' (CDC-RFA-
PS10-10138).
--CFDA Number 93.523 The Affordable Care Act: Human Immunodeficiency 
Virus (HIV) Prevention and Public Health Fund Activities is the PPACA-
specific CFDA number for this initiative. It is included in addition to 
the CFDA Number 93.940, HIV Prevention Activities for Health 
Departments, published in the above-referenced Funding Opportunity 
Announcement (FOA).
    Award Information:
    Type of Award: Cooperative Agreement.
    Fiscal Year Funds: Fiscal Year 2010, Funding for this announcement 
will include a combination of HIV Prevention funding and funds from the 
PPACA, Prevention and Public Health Fund. Available funding amounts, 
including the additional PPHF funds, are as follows.

Part A--HIV Screening and HIV Counseling, Testing, and Referral

    Approximate Current Fiscal Year Funding: Up to $60,000,000 total 
(to include up to $55,633,000 in Enhanced HIV Testing funds and adding 
$4,367,000 in Patient Protection and Affordable Care Act of 2010 
funds).
    Approximate Total Project Period Funding: $166,899,000. (This 
amount is an estimate, and is subject to availability of funds. This 
amount includes direct and indirect costs.)
    Approximate Number of Awards: 30.
    Approximate Average Award: $2,000,000. The average awards will be 
proportionately based on estimated combined 2007 Black/African American 
and Hispanic/Latino AIDS diagnoses for eligible jurisdictions. (These 
amounts are for the first 12-month budget period, and include both 
direct and indirect costs.)
    Floor and Ceiling of Individual Award Ranges:

------------------------------------------------------------------------
                                          Floor of       REVISED Ceiling
            Jurisdiction              individual award    of individual
                                            range         award range*
------------------------------------------------------------------------
Florida.............................        $4,307,446        $6,818,721
New York City.......................         3,998,517         6,329,161
California..........................         2,482,306         3,926,423
Texas...............................         2,094,529         3,311,912
New York State......................         1,861,862         2,943,206
Georgia.............................         1,788,184         2,826,449
Maryland............................         1,700,288         2,687,160
North Carolina......................         1,303,462         2,058,310
Louisiana...........................         1,302,170         2,056,262
Puerto Rico.........................         1,258,222         1,986,618
Houston.............................         1,197,470         1,890,344
District of Columbia................         1,140,596         1,800,216
New Jersey..........................         1,059,163         1,671,169
Philadelphia........................         1,042,359         1,644,540
South Carolina......................           985,485         1,554,411
Chicago.............................           968,681         1,527,782
Virginia............................           852,348         1,343,429
Los Angeles.........................           803,229         1,265,591
Pennsylvania........................           801,937         1,263,543
Michigan............................           798,059         1,257,398
Tennessee...........................           774,792         1,220,527
Illinois............................           707,578         1,114,012
Ohio................................           684,311         1,077,141
Massachusetts.......................           667,507         1,050,512
Alabama.............................           642,948         1,011,593
Mississippi.........................           605,463           952,191
Connecticut.........................           602,878           948,093
Missouri............................           549,881           864,111
Arizona.............................           542,126           851,820
San Francisco.......................           476,204           747,353
------------------------------------------------------------------------
* These ceilings are for the first 12-month budget period and include
  direct and indirect costs.

Part B--Enhanced Linkage to Medical Care and Partner Services

    Approximate Current Fiscal Year Funding: $4,000,000.
    Approximate Total Project Period Funding: $12,000,000 (This amount 
is an estimate, and is subject to availability of funds. This amount 
includes direct and indirect costs.)
    Approximate Number of Awards: Up to 20.
    Approximate Average Award: $200,000 (This amount is for the first 
12-month budget period, and includes both direct and indirect costs.)
    Floor of Individual Award Range: $ 150,000.
    Ceiling of Individual Award Range: $ 225,000 (This ceiling is for 
the first 12-month budget period and includes direct and indirect 
costs.)

Both Part A (HIV Screening and HIV Counseling, Testing, and Referral) 
and Part B (Enhanced Linkage to Medical Care and Partner Services)

    Anticipated Award Date: September 30, 2010.
    Budget Period Length: 12 months.
    Project Period Length: 3 years (Availability of PPACA funds beyond 
the initial 12 months will be based on availability of future funding.)

[[Page 51275]]

    Throughout the project period, CDC's commitment to continuation of 
awards will be conditioned on the availability of funds, evidence of 
satisfactory progress by the recipient (as documented in required 
reports), and the determination that continued funding is in the best 
interest of the Federal government.

Application Selection Process

    CDC will apply the same selection methodology published in the CDC-
RFA-PS10-10138.

Funding Authority

    CDC will add the PPACA Authority to that which is currently 
reflected in the published Funding Opportunity CDC-RFA-PS10-10138. The 
revised funding authority language will read:
--This program is authorized under Sections 301 and 318 of the Public 
Health Service Act (42 U.S.C. Section 241 and 247c), as amended, and 
Section 4002 of the Patient Protection and Affordable Care Act (Pub. L. 
111-148).

DATES: The effective date for this action is August 19, 2010 and 
remains in effect until the expiration of the project period of the 
PPACA funded applications.

FOR FURTHER INFORMATION CONTACT: Elmira Benson, Acting Deputy Director, 
Centers for Disease Control and Prevention, 2920 Brandywine Road, 
Atlanta, GA 30341, telephone (770) 488-2802, e-mail: 
Elmira.Benson@cdc.gov.

SUPPLEMENTARY INFORMATION: On March 23, 2010, the President signed into 
law the Patient Protection and Affordable Care Act (PPACA), Public Law 
111-148. PPACA is designed to improve and expand the scope of health 
care coverage for Americans. Cost savings through disease prevention is 
an important element of this legislation and PPACA has established a 
Prevention and Public Health Fund (PPHF) for this purpose. 
Specifically, the legislation states in Section 4002 that the PPHF is 
to ``provide for expanded and sustained national investment in 
prevention and public health programs to improve health and help 
restrain the rate of growth in private and public sector health care 
costs.'' PPACA and the Prevention and Public Health Fund make improving 
public health a priority with investments to improve public health.
    The PPHF states that the Secretary shall transfer amounts in the 
Fund to accounts within the Department of Health and Human Services to 
increase funding, over the fiscal year 2008 level, for programs 
authorized by the Public Health Service Act, for prevention, wellness 
and public health activities including prevention research and health 
screenings, such as the Community Transformation Grant Program, the 
Education and Outreach Campaign for Preventative Benefits, and 
Immunization Programs.
    PPACA legislation affords an important opportunity to advance 
public health across the lifespan and to reduce health disparities by 
supporting an intensive community approach to chronic disease 
prevention and control.
    Therefore, increasing funding available to applicants under this 
FOA using the PPHF to further HIV prevention programs is consistent 
with the purpose of the PPHF, as stated above, to provide for an 
expanded and sustained national investment in prevention and public 
health programs. Further, the Secretary allocated funds to CDC, 
pursuant to the PPHF, for the types of activities this FOA is designed 
to carry out.

    Dated: August 13, 2010.
Tanja Popovic, MD, PhD, F(AMM), AM(AAFS),
Deputy Associate Director for Science, Centers for Disease Control and 
Prevention.
[FR Doc. 2010-20572 Filed 8-18-10; 8:45 am]
BILLING CODE P